Manulife (Manufacturers Life Insurance)
IMUC

Manulife (Manufacturers Life Insurance)’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-56
Closed – – 4510
2017
Q2 		$0 Buy
56
+5
+10% +$8 ﹤0.01% 4607
2017
Q1 		$0 Hold
51
– – ﹤0.01% 4530
2016
Q4 		$0 Sell
51
-1
-2% -$3 ﹤0.01% 4598
2016
Q3 		$0 Hold
52
– – ﹤0.01% 4497
2016
Q2 		$0 Hold
52
– – ﹤0.01% 4502
2016
Q1 		$1K Hold
52
– – ﹤0.01% 4091
2015
Q4 		$1 Hold
52
– – ﹤0.01% 3995
2015
Q3 		$1 Hold
52
– – ﹤0.01% 4040
2015
Q2 		$1 Hold
52
– – ﹤0.01% 4013
2015
Q1 		$1 Hold
52
– – ﹤0.01% 3978
2014
Q4 		$2 Hold
52
– – ﹤0.01% 3797
2014
Q3 		$2 Hold
52
– – ﹤0.01% 3820
2014
Q2 		$2K Hold
52
– – ﹤0.01% 3756
2014
Q1 		$3 Hold
52
– – ﹤0.01% 3623
2013
Q4 		$2 Hold
52
– – ﹤0.01% 3719
2013
Q3 		$5 Hold
52
– – ﹤0.01% 3387
2013
Q2 		$4K Buy
+52
New +$4.98K ﹤0.01% 3346

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s IMUC Position: Q3 2017 in Review

Manulife (Manufacturers Life Insurance) sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2017, closing a stake of 56 shares.

Manulife (Manufacturers Life Insurance) first reported a position in IMUC in Q2 2013 and held it in 17 quarters. The position peaked at $4K in Q2 2013. 18 funds tracked by Wall St. Rank hold IMUC as of Q3 2017.

  • Manulife (Manufacturers Life Insurance) reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2017 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 56 ImmunoCellular Therapeutics, Ltd. shares in Q3 2017.
  • Manulife (Manufacturers Life Insurance) first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 17 quarters.
  • Manulife (Manufacturers Life Insurance)'s ImmunoCellular Therapeutics, Ltd. position peaked at $4K in Q2 2013.
  • 18 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2017.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q3 2017, filed 14 Nov 2017.